“DOSTARLIMAB” GIVES A 100 PERCENT SUCCESS RATE IN CLINICAL TRIALS
Doctors are in a state of shock after learning that a new medicine being evaluated for colorectal cancer has a clinical trial success rate of 100 percent.
Dostarlimab, a medication made in a lab that functions as a surrogate for antibodies in the human body, astounded researchers when all 18 participants were deemed to be in remission one year following the drug study.
Physical examinations, endoscopies, PET scans, and MRI scans were performed by doctors, but they were unable to detect any signs of cancer in their bodies.
This was “the first time this has happened in the history of cancer,” according to Dr. Luis A. Diaz Jr. of the Memorial Sloan Kettering Cancer Center in New York.
